Clinical Trial Update: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequential nivolumab and ipilimumab in advanced/metastatic melanoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced or Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-04-11